Pulmonology

This new data may help clinicians not to over-treat or over-medicalize with infants that have a SARS-CoV-2 infection.

Amid the escalating threat of wildfires due to climate change, the medical and public health communities face an increasing responsibility to develop robust emergency response plans to safeguard patients and healthcare infrastructure.

This action represents the first occurrence of the FDA pursuing civil money penalties for the maximum amount against e-cigarette retailers for such an offense.

Granted a PDUFA date in March 2024, if approved, sotatercept would be a first-in-class medication to address the rare and progressive disease.

New research on the effects of the Canadian wildfires on asthma syndrome in patients sheds light on the downstream effects of ecological disaster on regions outside of those affected.

This new research concluded that the unclear nature of safety outcomes indicated additional research and enhanced monitoring of patients’ adverse events may be necessary.

The UT Health infectious disease specialist reviews new vaccine and treatment options, as well as the threat of an RSV-flu-COVID "triple-epidemic" in this winter season.

This new data expands upon limited current research on environmental elements that contribute to the extensive variation in symptoms and infection frequency seen in children.

This new Morbidity and Mortality Weekly Report on the CDC site indicates the importance of influenza vaccination, especially for at-risk populations.

This new research indicates that children with ARDS surviving discharge have a higher probability of readmission than was reported previously among the pediatric intensive care unit population.

At ERS International Congress 2023, new data related to use of sotatercept offered providers additional insight into the effects of the agent in people with PAH.

This research was the result of the first study assessing adaptive smoking cessation treatment within a clinical population using very few criteria for exclusion.

An analysis of more than 4000 adolescents and young adults in the US found those who more recently used tobacco products reported more symptoms than other users.

In the latest episode of Lungcast, the diagnosis, classifciation and treatment of PE—namely blood clots—is comprehensively dissected by the Lewis Katz School of Medicine clinician and investigator.

This new data supports the use and feasibility of clinicians using longitudinal tobacco cessation care in the lung cancer screening setting.

This new analysis demonstrated the importance of carefully considering the unintended results of removing race correction from PFTs to prevent exacerbating disparities among Black patients.

This new data indicated a necessity for clinical strategies made to handle unintentional pathogenic or likely pathogenic germline variants seen in tumor-only next-generation sequencing.

This new research indicates that while there are ongoing trials seeking to define which individuals with subsegmental PE may be surveilled, greater uptake of newer surveillance actions may necessitate more than passive diffusion.

A study led by Massachusetts General Hospital is offering insight into the antibody response achieved with each dose of mRNA vaccines among heart and lung transplant recipients relative to their healthy counterparts.

This new research further highlights the importance of addressing traffic pollution as an environmental justice issue, as it impacts pregnancies and leads to disparities in traffic-related exposure levels.

A year of research emphasizes the significance of collaboration, standardized approaches, and targeted therapies in rare pulmonary diseases.

Certain craniofacial measurements identified by lateral cephalograms exhibit notable variations in patients with obstructive sleep apnea, providing potential indicators for early diagnosis.

If approved, OFEV (nintedanib) would be the first and only approved treatment for children and adolescents aged 6-17 years old with fibrosing interstitial lung disease.

New Study Reveals Efficacy of Bevacizumab in Treating Severe Cases of Pulmonary Papillomatosis.

Days with a combination of a heat wave and high fine particulate matter air pollution may double the risk of a fatal heart attack, says new research.